Emixustat hydrochloride is under clinical development by Kubota Vision and currently in Phase II for Proliferative Diabetic Retinopathy (PDR). According to GlobalData, Phase II drugs for Proliferative Diabetic Retinopathy (PDR) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Emixustat hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emixustat hydrochloride overview
Emixustat hydrochloride (ACU-4429) is under development for the treatment of juvenile macular degeneration (Stargardt disease) and proliferative diabetic retinopathy. It is administered through oral route in the form of tablet and acts by targeting RPE65. The drug candidate is a non-retinoid visual cycle modulator (VCM) being developed based on visual cycle modulation (VCM) technology.
The drug candidate was under development for the treatment of geographic atrophy associated with dry age-related macular degeneration and age-related macular degeneration.
Kubota Vision overview
Kubota Vision, a subsidiary of Kubota Pharmaceutical Holding, is a developer of treatments for degenerative eye diseases and a pharmaceutical compound screening system. The company develops products using its visual cycle modulation technology. It offers emixustat hydrochloride which is used for geographic atrophy secondary and related dry age-related macular degeneration. The company offers drug candidates for the treatment of geographic atrophy, proliferative diabetic retinopathy, retinitis pigmentosa, cataract, and glaucoma. It develops drugs and devices to preserve and restore vision. Kubota Vision is headquartered in Seattle, Washington, the US.
For a complete picture of Emixustat hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
